CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer.
Xu H, Gitto SB, Ho GY, Medvedev S, Shield-Artin K, Kim H, Beard S, Kinose Y, Wang X, Barker HE, Ratnayake G, Hwang WT; Australian Ovarian Cancer Study; Hansen RJ, Strouse B, Milutinovic S, Hassig C, Wakefield MJ, Vandenberg CJ, Scott CL, Simpkins F.
Xu H, et al. Among authors: medvedev s.
iScience. 2024 May 15;27(7):109978. doi: 10.1016/j.isci.2024.109978. eCollection 2024 Jul 19.
iScience. 2024.
PMID: 39021796
Free PMC article.